CN101357134A - 抗肿瘤效果增强剂和抗肿瘤剂 - Google Patents

抗肿瘤效果增强剂和抗肿瘤剂 Download PDF

Info

Publication number
CN101357134A
CN101357134A CNA2008101445581A CN200810144558A CN101357134A CN 101357134 A CN101357134 A CN 101357134A CN A2008101445581 A CNA2008101445581 A CN A2008101445581A CN 200810144558 A CN200810144558 A CN 200810144558A CN 101357134 A CN101357134 A CN 101357134A
Authority
CN
China
Prior art keywords
tegafur
potassium
antitumor
oxonate
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008101445581A
Other languages
English (en)
Chinese (zh)
Inventor
内田淳二
首藤光洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN101357134A publication Critical patent/CN101357134A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2008101445581A 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂 Pending CN101357134A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14
JP2003070097 2003-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800069779A Division CN1761665A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Publications (1)

Publication Number Publication Date
CN101357134A true CN101357134A (zh) 2009-02-04

Family

ID=32984641

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008101445581A Pending CN101357134A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂
CNA2004800069779A Pending CN1761665A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004800069779A Pending CN1761665A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Country Status (21)

Country Link
US (2) US9611227B2 (enExample)
EP (1) EP1604991B1 (enExample)
JP (1) JP4610481B2 (enExample)
KR (1) KR100812693B1 (enExample)
CN (2) CN101357134A (enExample)
AT (1) ATE408408T1 (enExample)
AU (1) AU2004220205B2 (enExample)
BR (1) BRPI0408372A (enExample)
CA (1) CA2518195C (enExample)
CY (1) CY1108395T1 (enExample)
DE (1) DE602004016636D1 (enExample)
DK (1) DK1604991T3 (enExample)
ES (1) ES2312978T3 (enExample)
MX (1) MXPA05009781A (enExample)
NZ (1) NZ542150A (enExample)
PL (1) PL1604991T3 (enExample)
PT (1) PT1604991E (enExample)
RU (1) RU2334517C2 (enExample)
SI (1) SI1604991T1 (enExample)
TW (1) TW200503720A (enExample)
WO (1) WO2004081012A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137640A1 (en) * 2005-04-01 2009-05-28 Taiho Pharmaceutical Co.Ltd Potentiator for radiation therapy comprising pyridine derivative as active ingredient
EP1864683B1 (en) * 2005-04-01 2010-09-01 Taiho Pharmaceutical Co., Ltd. Radiotherapy enhancer
JPWO2007043531A1 (ja) * 2005-10-07 2009-04-16 セレスター・レキシコ・サイエンシズ株式会社 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
JP5566376B2 (ja) * 2009-04-22 2014-08-06 大鵬薬品工業株式会社 腎細胞癌に対する化学療法の治療効果予測方法
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
BR112013030093B1 (pt) * 2011-05-25 2019-12-10 Taiho Pharmaceutical Co Ltd comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico
EP3053578B1 (en) * 2013-09-30 2020-12-23 Taiho Pharmaceutical Co., Ltd. Combination cancer therapy using azabicyclo compound
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443028B1 (en) * 1989-01-05 1993-09-29 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
DE69121551T2 (de) * 1990-09-07 1997-01-02 Taiho Pharmaceutical Co Ltd Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
KR0148589B1 (ko) * 1991-05-27 1998-11-02 고바야시 유끼오 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
WO2001066102A2 (en) * 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
EP1368034A1 (en) 2001-03-06 2003-12-10 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JPWO2003004640A1 (ja) * 2001-07-05 2004-10-28 大鵬薬品工業株式会社 抗癌剤感受性測定用ｄｎａアレイ

Also Published As

Publication number Publication date
EP1604991B1 (en) 2008-09-17
DE602004016636D1 (de) 2008-10-30
JP4610481B2 (ja) 2011-01-12
DK1604991T3 (da) 2009-01-05
ATE408408T1 (de) 2008-10-15
RU2005131839A (ru) 2006-02-10
TW200503720A (en) 2005-02-01
US9611227B2 (en) 2017-04-04
NZ542150A (en) 2009-09-25
JPWO2004081012A1 (ja) 2006-06-08
AU2004220205A1 (en) 2004-09-23
KR100812693B1 (ko) 2008-03-13
MXPA05009781A (es) 2005-10-26
US20060116345A1 (en) 2006-06-01
TWI295173B (enExample) 2008-04-01
PT1604991E (pt) 2008-10-27
RU2334517C2 (ru) 2008-09-27
WO2004081012A1 (ja) 2004-09-23
KR20050106119A (ko) 2005-11-08
AU2004220205B2 (en) 2010-06-17
SI1604991T1 (sl) 2009-02-28
ES2312978T3 (es) 2009-03-01
EP1604991A1 (en) 2005-12-14
US20170157131A1 (en) 2017-06-08
BRPI0408372A (pt) 2006-03-21
CA2518195A1 (en) 2004-09-23
US9814724B2 (en) 2017-11-14
CA2518195C (en) 2009-07-07
EP1604991A4 (en) 2006-05-03
PL1604991T3 (pl) 2009-02-27
CN1761665A (zh) 2006-04-19
CY1108395T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
HK1127546A (en) Antitumor effect potentiator and antitumor agent
CN115444938A (zh) cGAS抑制剂与化疗药物联合在制备治疗肺癌药物中的用途
HK40054116A (en) Pharmaceutical combination preparation for treating terminal non-small cell lung cancer patients with brain metastasis
CN108135894A (zh) 肿瘤治疗剂
HK1104780A (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1127546

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20090204

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1127546

Country of ref document: HK